Determinants of success and failure of antibody-based strategies against respiratory viruses: insights from RSV and SARS-CoV-2
Hai Guo, Hongshu Wang, Shutong Wu, Haonan Lin, Guosong Wang, Qiang Pu · 2026
Read Determinants of success and failure of antibody-based strategies against respiratory viruses: insights from RSV and SARS-CoV-2 by Hai Guo, Hongshu Wang, Shutong Wu, Haonan Lin, Guosong Wang, Qiang Pu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13176164.txt.
Description
Hai Guo and co-authors contrast in a 2026 review why antibody drugs triumphed against one lung virus and failed against another. A long-acting antibody shields infants from RSV, the first virus, cutting hospital stays by up to nine tenths with no escape seen. Every such drug against the COVID virus, by contrast, was obsolete within three years.
The team draws four rules: aim at a spot the virus cannot change without cost, reach the airway in force, beware single-spot plans, and use the antibody tail's help wisely. New routes, like inhaled or gene-sent antibodies, may beat the limits.
Catalog record
| CREATOR | Hai Guo, Hongshu Wang, Shutong Wu, Haonan Lin, Guosong Wang, Qiang Pu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |